Objectives：This naturalistic retrospective study investigated the effectiveness of ziprasidone measured by mean improvements of the Clinical Global Impression (CGI-I). Secondary objectives included prescribing patterns, tolerability and safety. Methods：From May to July 2006, 98 psychiatric patients who have been taking ziprasidone for at least 2 weeks were selected. Their current clinical statuses were assessed by the interview and laboratory tests including electrocardiogram (ECG). Data on DSM-IV diagnoses, dosing, concomitant psychotropic medications, clinical changes, adverse effects, and laboratory findings were collected retrospectively. Results：Ziprasidone was mostly prescribed for a switch from another antipsychotics for the treatment of schizophrenia. Two main reasons for a switch were unsatisfactory efficacy and poor tolerance, especially weight gain, of the preceding antipsychotic medication. Participants as a whole showed mean 2.7±1.0 of the CGI-Improvement. Significant weight reduction after switching to ziprasidone occurred, which was related to the clinical improvement. No significant increase of the QTc interval except one case was observed. Conclusion：The present study confirmed previous tolerability and safety data of ziprasidone as well as the results of its effectiveness.
서 론
대상 및 방법
결 과
고 찰
결 론
REFERENCES